Guggenheim analyst sees significant upside in Metsera stock to $56. MTSR is working on both injectable and oral weight-loss ...
Wall Street analysts initiated coverage on Metsera with bullish outlook given the biotech firm’s differentiated obesity drug pipeline and potential for significant upside. Metsera is also viewed as a ...
Guggenheim has initiated Metsera at buy saying that the biotech's pipeline of injectable and oral nutrient stimulated hormone ...
Metsera’s GLP-1 peptide has a long half-life, meaning it could be administered once a month. The company is ready to scale up ...
Weight-loss drug developer Metsera has raised $275 million after pricing its U.S. initial public offering at $18 per share, above its targeted range, the ARCH Venture Partners-backed biotech company ...
Metsera, which is developing weight-loss drugs, said on Monday it is seeking a valuation of up to $1.78 billion in its U.S. IPO, aiming to capitalize on Wall Street's insatiable appetite for such ...
By Prakhar Srivastava and Pritam Biswas (Reuters) -Metsera, which is developing weight-loss drugs, said on Monday it is seeking a valuation of up to $1.78 billion in its U.S. IPO, aiming to ...
The biotech recently linked the injectable candidate to weight loss of up to 11.3% after 12 weeks in a phase 2a trial. MET-097i also demonstrated a half-life of about 15 to 16 days, which Metsera ...
(Reuters) -Metsera, which is developing weight-loss drugs, said on Monday it is seeking a valuation of up to $1.78 billion in its U.S. IPO, aiming to capitalize on Wall Street's insatiable ...
At the beginning of January, Metsera reported preliminary Phase 2a data showing the drug led to dose-dependent weight loss. At the high dose, the average placebo-adjusted weight loss from the ...
(Reuters) -Shares of weight-loss drug developer Metsera surged nearly 42% in a strong Nasdaq debut on Friday, valuing the ARCH Venture Partners-backed biotech firm at $2.68 billion. The strong market ...